JP5859854B2 - ウイルス感染および細菌感染の一体検出のための方法および装置 - Google Patents
ウイルス感染および細菌感染の一体検出のための方法および装置 Download PDFInfo
- Publication number
- JP5859854B2 JP5859854B2 JP2011528055A JP2011528055A JP5859854B2 JP 5859854 B2 JP5859854 B2 JP 5859854B2 JP 2011528055 A JP2011528055 A JP 2011528055A JP 2011528055 A JP2011528055 A JP 2011528055A JP 5859854 B2 JP5859854 B2 JP 5859854B2
- Authority
- JP
- Japan
- Prior art keywords
- sample
- reagent
- region
- mxa
- line
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000001514 detection method Methods 0.000 title claims description 57
- 208000035143 Bacterial infection Diseases 0.000 title claims description 33
- 208000022362 bacterial infectious disease Diseases 0.000 title claims description 32
- 208000036142 Viral infection Diseases 0.000 title claims description 31
- 238000000034 method Methods 0.000 title claims description 23
- 230000003612 virological effect Effects 0.000 title description 66
- 238000012360 testing method Methods 0.000 claims description 122
- 239000003153 chemical reaction reagent Substances 0.000 claims description 92
- 239000003550 marker Substances 0.000 claims description 84
- 238000009739 binding Methods 0.000 claims description 47
- 230000027455 binding Effects 0.000 claims description 46
- 239000003795 chemical substances by application Substances 0.000 claims description 41
- 238000007689 inspection Methods 0.000 claims description 40
- 230000009089 cytolysis Effects 0.000 claims description 19
- 230000009385 viral infection Effects 0.000 claims description 18
- 241000700605 Viruses Species 0.000 claims description 14
- 238000011144 upstream manufacturing Methods 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 210000000265 leukocyte Anatomy 0.000 claims description 11
- 238000004090 dissolution Methods 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 4
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 4
- 239000011886 peripheral blood Substances 0.000 claims description 4
- 210000000959 ear middle Anatomy 0.000 claims description 3
- 230000001580 bacterial effect Effects 0.000 description 61
- 230000002934 lysing effect Effects 0.000 description 37
- 101001128393 Homo sapiens Interferon-induced GTP-binding protein Mx1 Proteins 0.000 description 27
- 102100031802 Interferon-induced GTP-binding protein Mx1 Human genes 0.000 description 26
- 239000002904 solvent Substances 0.000 description 26
- 239000007788 liquid Substances 0.000 description 24
- 108010074051 C-Reactive Protein Proteins 0.000 description 23
- 102100032752 C-reactive protein Human genes 0.000 description 23
- 230000032258 transport Effects 0.000 description 22
- 239000000463 material Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 230000000875 corresponding effect Effects 0.000 description 10
- 238000003018 immunoassay Methods 0.000 description 10
- 230000002452 interceptive effect Effects 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000011065 in-situ storage Methods 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000003599 detergent Substances 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000295 complement effect Effects 0.000 description 6
- 239000004816 latex Substances 0.000 description 6
- 229920000126 latex Polymers 0.000 description 6
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000002421 cell wall Anatomy 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 238000011179 visual inspection Methods 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 4
- 206010057190 Respiratory tract infections Diseases 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 102000013446 GTP Phosphohydrolases Human genes 0.000 description 3
- 108091006109 GTPases Proteins 0.000 description 3
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 230000029586 bacterial cell surface binding Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 either IFNγ Proteins 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000467 Interferon-beta Proteins 0.000 description 2
- 102000003996 Interferon-beta Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000000104 diagnostic biomarker Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 238000012123 point-of-care testing Methods 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102000007445 2',5'-Oligoadenylate Synthetase Human genes 0.000 description 1
- 108010086241 2',5'-Oligoadenylate Synthetase Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 108010077840 Complement C3a Proteins 0.000 description 1
- 101800000115 Copeptin Proteins 0.000 description 1
- 102400000060 Copeptin Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- QRLVDLBMBULFAL-UHFFFAOYSA-N Digitonin Natural products CC1CCC2(OC1)OC3C(O)C4C5CCC6CC(OC7OC(CO)C(OC8OC(CO)C(O)C(OC9OCC(O)C(O)C9OC%10OC(CO)C(O)C(OC%11OC(CO)C(O)C(O)C%11O)C%10O)C8O)C(O)C7O)C(O)CC6(C)C5CCC4(C)C3C2C QRLVDLBMBULFAL-UHFFFAOYSA-N 0.000 description 1
- 101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 1
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010034839 Pharyngitis streptococcal Diseases 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010048233 Procalcitonin Proteins 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 102000004903 Troponin Human genes 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000021240 acute bronchiolitis Diseases 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002967 competitive immunoassay Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- UVYVLBIGDKGWPX-KUAJCENISA-N digitonin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)C[C@@H](O)[C@H](O[C@H]5[C@@H]([C@@H](O)[C@@H](O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)CO7)O)[C@H](O)[C@@H](CO)O6)O[C@H]6[C@@H]([C@@H](O[C@H]7[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O7)O)[C@@H](O)[C@@H](CO)O6)O)[C@@H](CO)O5)O)C[C@@H]4CC[C@H]3[C@@H]2[C@@H]1O)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 UVYVLBIGDKGWPX-KUAJCENISA-N 0.000 description 1
- UVYVLBIGDKGWPX-UHFFFAOYSA-N digitonine Natural products CC1C(C2(CCC3C4(C)CC(O)C(OC5C(C(O)C(OC6C(C(OC7C(C(O)C(O)CO7)O)C(O)C(CO)O6)OC6C(C(OC7C(C(O)C(O)C(CO)O7)O)C(O)C(CO)O6)O)C(CO)O5)O)CC4CCC3C2C2O)C)C2OC11CCC(C)CO1 UVYVLBIGDKGWPX-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 102000048122 human MX1 Human genes 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- YYELLDKEOUKVIQ-UHFFFAOYSA-N octaethyleneglycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCO YYELLDKEOUKVIQ-UHFFFAOYSA-N 0.000 description 1
- HEGSGKPQLMEBJL-RKQHYHRCSA-N octyl beta-D-glucopyranoside Chemical compound CCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HEGSGKPQLMEBJL-RKQHYHRCSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 108010012004 proadrenomedullin Proteins 0.000 description 1
- 102000034567 proadrenomedullin Human genes 0.000 description 1
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000001429 visible spectrum Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
- G01N33/54387—Immunochromatographic test strips
- G01N33/54388—Immunochromatographic test strips based on lateral flow
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0825—Test strips
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
- Y10T436/25375—Liberation or purification of sample or separation of material from a sample [e.g., filtering, centrifuging, etc.]
Description
Claims (22)
- 感染が細菌によるものかウイルスによるものかを決定する方法であって、
前記方法は、
a)サンプルを採取する工程と、
b)前記サンプルをサンプル分析装置へと移す工程を備え、
前記サンプル分析装置が
試薬領域を備え、
前記試薬領域は、
細菌感染のための診断マーカーであるCRPに特異的な少なくとも1つの第1の試薬を備え、前記CRPは宿主生物によって生成されるものであり、これによって、前記サンプル中に存在する前記CRPが前記第1の試薬に触れると、第1の標識された複合体が形成され、
前記試薬領域は、
ウイルス感染のための診断マーカーであるMxAに特異的な少なくとも1つの第2の試薬を備え、前記MxAは宿主生物によって生成されるものであり、これによって、前記サンプル中に存在する前記MxAが前記第2の試薬に触れると、第2の標識された複合体が形成され、
前記試薬領域はさらに、
前記第1の標識された複合体と結合する第1の結合パートナーと、前記第2の標識された複合体と結合する第2の結合パートナーとを含む検出領域を備え、
前記方法はさらに、
c)前記CRPおよび/または前記MxAの存在に関して前記サンプルを分析する工程を備えることを特徴とする方法。 - 前記工程c)が
i)前記サンプルを前記サンプル分析装置上で溶出する工程と、
ii)前記検出領域から結果を視覚的に測定する工程を備えることを特徴とする請求項1に記載の方法。 - 前記MxAまたは前記CRPの前記存在は、肉眼で見える前記検出領域内に配された検査ラインによって示されることを特徴とする請求項1に記載の方法。
- サンプルがCRPに対し陽性の場合、前記検出領域内に配された第1の検査ラインによって肉眼で見え、サンプルがMxAに対し陽性の場合、前記存在が前記検出領域内に配された第2の検査ラインによって肉眼で見えることを特徴とする請求項1に記載の方法。
- 前記第1の検査ラインは陽性の際に第1の色を表示し、前記第2の検査ラインは陽性の際に前記第1の色とは異なる第2の色を表示することを特徴とする請求項4に記載の方法。
- 前記第1の検査ラインと前記第2の検査ラインの両方が前記サンプル分析装置上の同じ空間に配されることで、前記第1の検査ラインと前記第2の検査ラインの両方が陽性の際に、第3の色が形成されることを特徴とする請求項5に記載の方法。
- 前記第1の検査ラインは、前記サンプル分析装置上で前記第2の検査ラインと空間的に離れていることを特徴とする請求項4に記載の方法。
- 前記サンプルが血液サンプルであることを特徴とする請求項1に記載の方法。
- 前記サンプルが白血球を含むことを特徴とする請求項1に記載の方法。
- 前記サンプルが、末梢血、鼻咽頭吸引物、涙、髄液、および、中耳吸引物からなる群から選択される位置から採取されることを特徴とする請求項1に記載の方法。
- 細菌感染のための診断マーカーであるCRPまたはウイルス感染のための診断マーカーであるMxAの検出のための装置であって、前記CRPは宿主生物によって生成されるものであり、前記MxAは宿主生物によって生成されるものであり、
前記装置は、
a)サンプルを前記装置に塗布するためのサンプル塗布領域と、
b)試薬領域とを備え、
前記試薬領域は、
CRPに特異的な少なくとも1つの第1の試薬を備え、これによって、前記サンプル中に存在するCRPが前記第1の試薬に触れると、第1の標識された複合体が形成され、
前記試薬領域はさらに、
MxAに特異的な少なくとも1つの第2の試薬を備え、これによって、前記サンプル中に存在するMxAが前記第2の試薬に触れると、第2の標識された複合体が形成され、
前記装置はさらに、
c)検出領域を備え、
前記検出領域は、
前記第1の標識された複合体に結合する第1の結合パートナーと
前記第2の標識された複合体に結合する第2の結合パートナーとを備えることを特徴とする装置。 - 前記検出領域は、前記サンプルが前記CRPに関して陽性の際に肉眼で見える第1の検査ラインと、前記サンプルが前記MxAに関して陽性の際に肉眼で見える第2の検査ラインとを備えることを特徴とする請求項11に記載の装置。
- 前記第1の検査ラインは前記第2の検査ラインから空間的に離れていることを特徴とする請求項12に記載の装置。
- 前記第1の検査ラインは陽性の際に第1の色を表示し、前記第2の検査ラインは陽性の際に前記第1の色とは異なる第2の色を表示することを特徴とする請求項12に記載の装置。
- 前記第1の検査ラインと前記第2の検査ラインの両方が同じ空間に配されることで、前記第1の検査ラインと前記第2の検査ラインの両方が陽性の際に、第3の色が形成されることを特徴とする請求項14に記載の装置。
- 前記検出領域は、前記装置が作動している際に肉眼で見える制御ラインを備えることを特徴とする請求項11に記載の装置。
- 前記サンプルが血液サンプルであることを特徴とする請求項11に記載の装置。
- 前記サンプルが白血球を含むことを特徴とする請求項11に記載の装置。
- 前記サンプルが、末梢血、鼻咽頭吸引物、涙、髄液、および、中耳吸引物からなる群から選択される位置から採取されることを特徴とする請求項11に記載の装置。
- 前記サンプル塗布領域が前記試薬領域と前記検出領域の上流にあり、前記検出領域が前記試薬領域の下流にあることを特徴とする請求項11に記載の装置。
- 少なくとも1つの溶解剤を含む溶解領域をさらに備え、
前記溶解領域が前記装置上で前記サンプルと接触することを特徴とする請求項11に記載の装置。 - 前記サンプル塗布領域が前記試薬領域の下流にあり、前記検出領域の上流にあることを特徴とする請求項11に記載の装置。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9893508P | 2008-09-22 | 2008-09-22 | |
US61/098,935 | 2008-09-22 | ||
US17905909P | 2009-05-18 | 2009-05-18 | |
US61/179,059 | 2009-05-18 | ||
US12/502,662 | 2009-07-14 | ||
US12/502,662 US8614101B2 (en) | 2008-05-20 | 2009-07-14 | In situ lysis of cells in lateral flow immunoassays |
PCT/US2009/057775 WO2010033963A2 (en) | 2008-09-22 | 2009-09-22 | Method and device for combined detection of viral and bacterial infections |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012503205A JP2012503205A (ja) | 2012-02-02 |
JP5859854B2 true JP5859854B2 (ja) | 2016-02-16 |
Family
ID=42040194
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011528055A Active JP5859854B2 (ja) | 2008-09-22 | 2009-09-22 | ウイルス感染および細菌感染の一体検出のための方法および装置 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8614101B2 (ja) |
EP (1) | EP2335072B1 (ja) |
JP (1) | JP5859854B2 (ja) |
ES (1) | ES2666350T3 (ja) |
WO (1) | WO2010033963A2 (ja) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2934220C (en) | 2007-10-02 | 2019-11-05 | Theranos, Inc. | Modular point-of-care devices and uses thereof |
US8609433B2 (en) | 2009-12-04 | 2013-12-17 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with sample compressor |
US8815609B2 (en) | 2008-05-20 | 2014-08-26 | Rapid Pathogen Screening, Inc. | Multiplanar lateral flow assay with diverting zone |
US20130196310A1 (en) | 2008-05-20 | 2013-08-01 | Rapid Pathogen Screening, Inc. | Method and Device for Combined Detection of Viral and Bacterial Infections |
US9068981B2 (en) | 2009-12-04 | 2015-06-30 | Rapid Pathogen Screening, Inc. | Lateral flow assays with time delayed components |
US8962260B2 (en) | 2008-05-20 | 2015-02-24 | Rapid Pathogen Screening, Inc. | Method and device for combined detection of viral and bacterial infections |
US20110086359A1 (en) * | 2008-06-10 | 2011-04-14 | Rapid Pathogen Screening, Inc. | Lateral flow assays |
AR085087A1 (es) | 2011-01-21 | 2013-09-11 | Theranos Inc | Sistemas y metodos para maximizar el uso de muestras |
AU2012278386B2 (en) * | 2011-07-05 | 2016-12-01 | Universiti Putra Malaysia (U.P.M) | A diagnostic kit for the detection of early acute leptospirosis |
US9523676B2 (en) * | 2011-08-24 | 2016-12-20 | Eiken Kagaku Kabushiki Kaisha | Leukocyte measurement device and reagent kit |
US9632102B2 (en) | 2011-09-25 | 2017-04-25 | Theranos, Inc. | Systems and methods for multi-purpose analysis |
US20140170735A1 (en) | 2011-09-25 | 2014-06-19 | Elizabeth A. Holmes | Systems and methods for multi-analysis |
US8840838B2 (en) | 2011-09-25 | 2014-09-23 | Theranos, Inc. | Centrifuge configurations |
US9664702B2 (en) | 2011-09-25 | 2017-05-30 | Theranos, Inc. | Fluid handling apparatus and configurations |
US8475739B2 (en) | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
US9619627B2 (en) | 2011-09-25 | 2017-04-11 | Theranos, Inc. | Systems and methods for collecting and transmitting assay results |
US9268915B2 (en) | 2011-09-25 | 2016-02-23 | Theranos, Inc. | Systems and methods for diagnosis or treatment |
US10012664B2 (en) | 2011-09-25 | 2018-07-03 | Theranos Ip Company, Llc | Systems and methods for fluid and component handling |
US9810704B2 (en) | 2013-02-18 | 2017-11-07 | Theranos, Inc. | Systems and methods for multi-analysis |
US9250229B2 (en) | 2011-09-25 | 2016-02-02 | Theranos, Inc. | Systems and methods for multi-analysis |
KR101523487B1 (ko) * | 2012-11-28 | 2015-05-27 | 후루카와 덴키 고교 가부시키가이샤 | 면역크로마토그래피, 이것에 이용되는 검출 장치 및 시약 |
DK2909331T3 (da) * | 2013-03-07 | 2019-08-19 | Rapid Pathogen Screening Inc | Fremgangsmåde og indretning til kombineret detektering af virus- og bakterieinfektioner |
CN104122397B (zh) * | 2013-04-27 | 2016-08-10 | 北京豪迈生物工程有限公司 | 超敏c反应蛋白荧光免疫层析法检测试剂盒及检测方法 |
EP3042208A4 (en) | 2013-09-06 | 2017-04-19 | Theranos, Inc. | Systems and methods for detecting infectious diseases |
CN105683751B (zh) | 2013-09-06 | 2020-01-17 | 赛拉诺斯知识产权有限责任公司 | 用于接收拭子的装置、系统、方法和套件 |
WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
US10444232B2 (en) | 2014-08-13 | 2019-10-15 | The Trustees Of Columbia University In The City Of New York | Diagnostic devices, systems, and methods |
MX2017005834A (es) | 2014-11-05 | 2017-11-17 | Voyager Therapeutics Inc | Polinucleotidos aad para el tratamiento de la enfermedad de parkinson. |
AU2015346162B2 (en) | 2014-11-14 | 2022-02-10 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
CN112375760A (zh) | 2014-11-14 | 2021-02-19 | 沃雅戈治疗公司 | 调节性多核苷酸 |
JP6788586B2 (ja) * | 2014-11-19 | 2020-11-25 | コーニンクレッカ フィリップス エヌ ヴェKoninklijke Philips N.V. | Hnlを用いる診断方法 |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
US10808287B2 (en) | 2015-10-23 | 2020-10-20 | Rapid Pathogen Screening, Inc. | Methods and devices for accurate diagnosis of infections |
US20180230489A1 (en) | 2015-10-28 | 2018-08-16 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448987A4 (en) | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
RU2764587C2 (ru) | 2016-05-18 | 2022-01-18 | Вояджер Терапьютикс, Инк. | Способы и композиции для лечения хореи гентингтона |
JP6945971B2 (ja) * | 2016-06-08 | 2021-10-06 | 株式会社ミズホメディー | 眼科領域における感染症検査のための検出キット |
WO2017221255A1 (en) | 2016-06-23 | 2017-12-28 | Memed Diagnostics Ltd. | Measuring trail by lateral flow immunoassay |
US11298041B2 (en) | 2016-08-30 | 2022-04-12 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
JP2020518258A (ja) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)治療組成物および方法 |
SG11201909868YA (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics Inc | Compositions and methods of treating huntington's disease |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
CN111132626B (zh) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | 轨迹阵列引导系统 |
KR20200044793A (ko) | 2017-08-03 | 2020-04-29 | 보이저 테라퓨틱스, 인크. | Aav의 전달을 위한 조성물 및 방법 |
JP2021502060A (ja) | 2017-10-16 | 2021-01-28 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | 筋萎縮性側索硬化症(als)の治療 |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
SI3489686T1 (sl) * | 2017-11-22 | 2021-04-30 | Dewact Labs Gmbh Abc Workspaces | Postopek in priprava za razlikovanje med virusnimi in bakterijskimi okužbami |
EP3762500A1 (en) | 2018-03-06 | 2021-01-13 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
US20210214749A1 (en) | 2018-05-16 | 2021-07-15 | Voyager Therapeutics, Inc. | Directed evolution |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
CN112567035A (zh) | 2018-07-02 | 2021-03-26 | 沃雅戈治疗公司 | 肌萎缩侧索硬化症及脊髓相关病症的治疗 |
US20210355454A1 (en) | 2018-07-24 | 2021-11-18 | Voyager Therapeutics, Inc. | Systems and methods for producing gene therapy formulations |
US20210348242A1 (en) | 2018-10-04 | 2021-11-11 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
AU2020208467A1 (en) | 2019-01-18 | 2021-08-05 | Voyager Therapeutics, Inc. | Methods and systems for producing AAV particles |
US10928394B2 (en) * | 2019-02-07 | 2021-02-23 | Julian R. K. Kage | Rapid test for lyme bacteria |
TW202106879A (zh) | 2019-04-29 | 2021-02-16 | 美商航海家醫療公司 | 於生物反應器中生產經桿狀病毒感染之昆蟲細胞(biic)之系統及方法 |
EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20220364114A1 (en) | 2019-08-26 | 2022-11-17 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
US20210172923A1 (en) | 2019-12-06 | 2021-06-10 | Spout | Devices, compositions and methods for use in detecting contaminating heavy metals in water sources |
CA3165294A1 (en) * | 2019-12-18 | 2021-06-24 | Rapid Pathogen Screening, Inc. | Selective white blood cell lysis for immunoassay systems |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
US20240141378A1 (en) | 2021-03-03 | 2024-05-02 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4094647A (en) * | 1976-07-02 | 1978-06-13 | Thyroid Diagnostics, Inc. | Test device |
DE3445816C1 (de) * | 1984-12-15 | 1986-06-12 | Behringwerke Ag, 3550 Marburg | Flaechenfoermiges diagnostisches Mittel |
US4960691A (en) * | 1986-09-29 | 1990-10-02 | Abbott Laboratories | Chromatographic test strip for determining ligands or receptors |
US5120643A (en) | 1987-07-13 | 1992-06-09 | Abbott Laboratories | Process for immunochromatography with colloidal particles |
US5985327A (en) | 1988-10-05 | 1999-11-16 | Flinders Technologies Pty. Ltd. | Solid medium and method for DNA storage |
US5972386A (en) | 1995-12-19 | 1999-10-26 | Flinders Technologies Pty, Ltd. | Dry solid medium for storage and analysis of genetic material |
US5807527A (en) | 1991-05-29 | 1998-09-15 | Flinders Technologies Pty. Ltd. | Solid medium and method for DNA storage |
US5496562A (en) | 1988-10-05 | 1996-03-05 | Flinders Technologies Pty Ltd | Solid medium and method for DNA storage |
US5756126A (en) | 1991-05-29 | 1998-05-26 | Flinders Technologies Pty. Ltd. | Dry solid medium for storage and analysis of genetic material |
US5607863A (en) * | 1991-05-29 | 1997-03-04 | Smithkline Diagnostics, Inc. | Barrier-controlled assay device |
US5869345A (en) | 1991-05-29 | 1999-02-09 | Smithkline Diagnostics, Inc. | Opposable-element assay device employing conductive barrier |
US5637469A (en) | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
US5714341A (en) | 1994-03-30 | 1998-02-03 | Epitope, Inc. | Saliva assay method and device |
EP0699906B1 (de) | 1994-07-25 | 2002-04-24 | Roche Diagnostics GmbH | Verfahren zum Nachweis der Kontamination einer Oberfläche mit einem Analyten |
US5695949A (en) | 1995-04-07 | 1997-12-09 | Lxn Corp. | Combined assay for current glucose level and intermediate or long-term glycemic control |
US5712172A (en) | 1995-05-18 | 1998-01-27 | Wyntek Diagnostics, Inc. | One step immunochromatographic device and method of use |
AU6248796A (en) | 1995-05-19 | 1996-11-29 | Universal Health-Watch, Inc. | Rapid self-contained assay format |
US20040110167A1 (en) | 1995-07-13 | 2004-06-10 | Gerdes John C. | Lateral flow system for nucleic acid detection |
JP2000502452A (ja) | 1995-12-22 | 2000-02-29 | ユニバーサル ヘルスウォッチ,インコーポレーテッド | 糞便の試験方法及び用具 |
DE19622503C2 (de) | 1996-06-05 | 1998-07-09 | Securetec Sicherheitstechnolog | Verfahren zum Nachweis von Analyten auf einer Oberfläche |
US6358752B1 (en) | 1996-09-27 | 2002-03-19 | Cornell Research Foundation, Inc. | Liposome-enhanced test device and method |
US5939252A (en) | 1997-05-09 | 1999-08-17 | Lennon; Donald J. | Detachable-element assay device |
US6106779A (en) | 1997-10-02 | 2000-08-22 | Biosite Diagnostics, Inc. | Lysis chamber for use in an assay device |
ATE273516T1 (de) | 1999-06-23 | 2004-08-15 | Cornell Res Foundation Inc | Entwässerung/rehydratisierung von markierten liposomen auf einer prüfeinrichtung |
US6350578B1 (en) | 1999-06-25 | 2002-02-26 | The Regents Of The University Of California | Method of quantitating dsDNA |
US6875619B2 (en) | 1999-11-12 | 2005-04-05 | Motorola, Inc. | Microfluidic devices comprising biochannels |
US6727073B1 (en) * | 1999-11-19 | 2004-04-27 | Binax, Inc. | Method for detecting enteric disease |
JP2002267670A (ja) * | 2001-03-07 | 2002-09-18 | Asahi Beer Yakuhin Kk | 特異的結合を利用する検体分析方法 |
DK1432786T3 (da) | 2001-09-06 | 2009-10-26 | Rapid Micro Biosystems Inc | Hurtig detektion af replikerede celler |
US20030186463A1 (en) | 2002-03-18 | 2003-10-02 | Robert Hudak | Method for clearing color and debris from or adding adjuvants or reactants to a selected portion of a chromatographic strip alone or in combination with a cell lysing step |
EP1489416A4 (en) | 2002-03-22 | 2005-09-28 | Kyowa Medex Co Ltd | METHOD FOR THE EVALUATION OF VIRUS INFECTION |
EP1525055A1 (en) | 2002-07-12 | 2005-04-27 | British Biocell International Limited | Lateral flow assay device and method |
US7135329B2 (en) | 2002-11-18 | 2006-11-14 | Princeton Biomeditech Corporation | Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients |
US7379167B2 (en) | 2003-02-11 | 2008-05-27 | International Technidyne Corporation | Hemoglobin test strip and analysis system |
US20040241779A1 (en) | 2003-02-24 | 2004-12-02 | Piasio Roger N. | Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays |
JP4566983B2 (ja) | 2003-02-24 | 2010-10-20 | バイナックス インコーポレイティッド | 乾式化学の側方流動−再構成されたクロマトグラフィー的酵素駆動式アッセイ法 |
US7393697B2 (en) | 2003-06-06 | 2008-07-01 | Advantage Diagnostics Corporation | Diagnostic test for analytes in a sample |
JP2005017248A (ja) | 2003-06-30 | 2005-01-20 | Asahi Breweries Ltd | 免疫クロマトグラフィー用分析装置 |
US7378285B2 (en) * | 2003-09-22 | 2008-05-27 | Paul Lambotte | Devices for the detection of multiple analytes in a sample |
CN1942577A (zh) | 2003-11-26 | 2007-04-04 | 比纳克斯公司 | 预测传染病状态的方法和试剂盒 |
JP5630936B2 (ja) | 2004-02-09 | 2014-11-26 | ラピッド パトゲン スクリーニング インコーポレイテッドRapid Pathogen Screening Inc. | ヒトの体液中のターゲットを特定することにより疾病を高速に検出する方法 |
NL1027737C2 (nl) | 2004-12-14 | 2006-06-16 | Teststrip B V | Chromatografische analyse-inrichting en test kit. |
US7297502B2 (en) * | 2004-12-17 | 2007-11-20 | Oakville Hong Kong Company Limited | Devices and methods for analyte assays with built-in result reporting using recognizable symbols |
JP4628110B2 (ja) * | 2005-01-06 | 2011-02-09 | シスメックス株式会社 | イムノクロマトグラフ法用試験具 |
US20070059682A1 (en) | 2005-09-13 | 2007-03-15 | Rapid Pathogen Screening Inc. | Method to increase specificity and/or accuracy of lateral flow immunoassays |
US7939342B2 (en) * | 2005-03-30 | 2011-05-10 | Kimberly-Clark Worldwide, Inc. | Diagnostic test kits employing an internal calibration system |
US20060240569A1 (en) | 2005-04-20 | 2006-10-26 | Becton, Dickinson And Company | Semi-quantitative immunochromatographic device |
US7618810B2 (en) | 2005-12-14 | 2009-11-17 | Kimberly-Clark Worldwide, Inc. | Metering strip and method for lateral flow assay devices |
EP1808696B1 (de) * | 2006-01-14 | 2009-03-11 | Roche Diagnostics GmbH | Immunologisches Testelement mit verbesserter Kontrollzone |
US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
JP2007322310A (ja) * | 2006-06-02 | 2007-12-13 | Nippon Kayaku Co Ltd | 検体中の分析対象物質の検出あるいは測定方法 |
AU2007280929B2 (en) | 2006-07-26 | 2012-03-22 | Abbott Rapid Diagnostics International Unlimited Company | Analysis device for biological sample |
GB2453356A (en) | 2007-10-03 | 2009-04-08 | James Homrig | Assay device comprising control analytes to confirm assay completion |
CA2761943A1 (en) | 2009-05-14 | 2010-11-18 | Streck, Inc. | Sample processing cassette, system, and method |
-
2009
- 2009-07-14 US US12/502,662 patent/US8614101B2/en active Active
- 2009-09-22 WO PCT/US2009/057775 patent/WO2010033963A2/en active Application Filing
- 2009-09-22 ES ES09815363.8T patent/ES2666350T3/es active Active
- 2009-09-22 JP JP2011528055A patent/JP5859854B2/ja active Active
- 2009-09-22 EP EP09815363.8A patent/EP2335072B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2010033963A3 (en) | 2010-06-24 |
US8614101B2 (en) | 2013-12-24 |
US20100015634A1 (en) | 2010-01-21 |
WO2010033963A2 (en) | 2010-03-25 |
EP2335072B1 (en) | 2018-01-17 |
EP2335072A4 (en) | 2012-03-14 |
JP2012503205A (ja) | 2012-02-02 |
ES2666350T3 (es) | 2018-05-04 |
EP2335072A2 (en) | 2011-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5859854B2 (ja) | ウイルス感染および細菌感染の一体検出のための方法および装置 | |
US9933423B2 (en) | Method and device for combined detection of viral and bacterial infections | |
AU2020233741B2 (en) | Method and device for combined detection of viral and bacterial infections | |
US10379121B2 (en) | Method and device for combined detection of viral and bacterial infections | |
US8962260B2 (en) | Method and device for combined detection of viral and bacterial infections | |
JP2012503170A (ja) | 側方流動イムノアッセイにおけるインサイツでの細胞の溶解 | |
US20120258469A1 (en) | Methods And Devices For Using Mucolytic Agents Including N-Acetyl Cysteine (NAC) | |
WO2021222610A2 (en) | Method and device for detection of severe acute respiratory syndrome coronavirus 2 using mxa proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120607 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130123 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130419 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131204 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150731 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151207 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151217 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5859854 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |